Aims: To screen the preeclampsia-related protein by proteomics. Methods: Proteomics was performed to identify differential protein expression profiles between normal full-term pregnancy, early-onset severe preeclampsia (ES-PE) or late-onset severe preeclampsia (LS-PE; n = 10 per group). Real-time quantitative PCR and immunohistochemistry were conducted to confirm the expression of α1-antitrypsin (α1-AT) in the decidual tissues of different subjects. ELISA was employed to detect the α1-AT content in the peripheral blood of 90 women (n = 30 per group). Results: We successfully constructed two-dimensional electrophoresis maps of decidual tissues, and a total of 20 differentially expressed proteins were identified. The α1-AT expression was different among the three groups. The normal full-term pregnancy women expressed the most α1-AT, and the LS-PE women expressed the least amount of α1-AT. The difference in the α1-AT expression was consistent with the proteomics data. The peripheral α1-AT content was the highest in the normal full-term pregnancy group (1.85 ± 0.15 g/l), moderate in the ES-PE group (0.77 ± 0.14 g/l) and lowest in the LS-PE group (0.42 ± 0.07 g/l; p < 0.05). Conclusion: Using 2D PAGE, we identified twenty proteins with significantly altered expression in PE. These differentially expressed proteins include prevention protein, in which α1-AT is downregulated in PE.

1.
Eyal YA, Suhail A, Mara S, Hamani Y, Schneider T, Al-Shareef W, Hochberg A, Ariel I: Growth factor receptor protein bound (GRB2) upregulation in the placenta in preeclampsia implies a possible role for ras signaling. Eur J Obstet Gynecol Reprod Biol 2005;118:174–181.
2.
Wagner LK: Diagnosis and management of preeclampsia. Am Fam Physician 2004;70:2317–2324.
3.
Zhang W, Chait BT: An expert system for protein identification using mass spectrometric peptide mapping information. Anal Chem 2000;72:2482–2489.
4.
Wessel G, Annelies R, Gouke J, Fetter WP, Sonderen L, De Vries JI, Wolf H: A randomised controlled trial comparing two temporizing management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG 2005;112:1358–1368.
5.
Koy C, Heitner JC, Woisch R, Kreutzer M, Serrano-Fernandez P, Gohlke R, Reimer T, Glocker MO: Cryodetector mass spectrometry profiling of plasma samples for HELLP diagnosis: an exploratory study. Proteomics 2005;5:3079–3087.
6.
Norwitz ER, Tsen LC, Park JS, Fitzpatrick PA, Dorfman DM, Saade GR, Buhimschi CS, Buhimschi IA: Discriminatory proteomic biomarker analysis identifies free hemoglobin in the cerebrospinal fluid of women with severe preeclampsia. Am J Obstet Gynecol 2005;193:957–964.
7.
Chen G, Zhang Y, Jin X, Zhang L, Zhou Y, Niu J, Chen J, Gu Y: Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin Appl 2011;5:300–310.
8.
Vascotto C, Salzano AM, D’Ambrosio C, Fruscalzo A, Marchesoni D, di Loreto C, Scaloni A, Tell G, Quadrifoglio F: Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia. Clin Chem 2007;6:160–170.
9.
Sun LZ, Yang NN, De W, Xiao YS: Proteomic analysis of proteins differentially expressed in preeclamptic trophoblasts. Gynecol Obstet Invest 2007;64:17–23.
10.
Gerke V, Moss SE: Annexins: from structure to function. Physiol Rev 2002;82:331–371.
11.
Sagara Y, Hirooka Y, Nozoe M, Ito K, Kimura Y, Sunagawa K: Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. J Hypertens 2007;25:399–406.
12.
Liu Y, Guo L, Zhang HL: To study relationship fibrinogen Bβ-148 (C→T) gene polymorphism and plasma fibrinogen levels and carotid atherosclerosis. J Apoplexy Nerv Dis 2006;23:528–530.
13.
Stoller JK, Aboussouan LS: Alpha-antitrypsin deficiency. Lancet 2005;365:22–25.
14.
Dati F, Pelzer H, Wagner C: Relevance of markers of hemostasis activation in obstetrics/gynecology and pediatrics. Semin Thromb Hemost 1998;24:443–448.
15.
Luff FC: Alpha-1-antitrypsin and its relevance to human disease. J Mol Med 1999;77:359–360.
16.
Xie Y, Xu GR, Zhang XH: Study on the relationship between serum α1-antitrypsin level and primary hepatocelluar carcinoma with alpha fetal protein negativity. Shanxi J Med Lab Sci 2001;4:13–14.
17.
Shi YP, Lv SM: Studies on the serum α1-antitrypsin change in patients with pregnancy-induced hypertension syndrome. Zhejiang Med J 2003;25:200–201.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.